Clinical trial
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or…
NCT00397579 · University of Texas Southwestern Medical Center, Other · Completed
Key facts
| NCT number | NCT00397579 |
|---|---|
| Title | DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes |
| Official title | Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND# 11314): a Phase I/II Clinical Trial |
| Lead sponsor | University of Texas Southwestern Medical Center, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm |
| Intervention type | Drug |
| Interventions | DT388IL3 |
| Enrollment | 11 |
| Start date | May 1, 2013 |
| Primary completion | Jul 27, 2017 |
| Completion | Jul 27, 2017 |
| First posted | Nov 9, 2006 |
| Last update posted | Apr 23, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: